ArticleScientific reports2026
Cardiometabolic multimorbidity prevalence and its socio-demographic determinants among Iranian adults: insights from the nationwide STEPS 2021.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiometabolic multimorbidity-typically defined as the presence of two or more cardiometabolic morbidities simultaneously-has emerged as a critical public health challenge both globally and in Iran. We analyzed data from the 2021 WHO STEPwise approach to NCD risk factor surveillance (STEPS) to determine its national prevalence and associated socio-demographic factors. Cardiometabolic multimorbidity was defined as having ≥ 2 of: hypertension (HTN), type 2 diabetes (T2DM), or history of MI/stroke. Multivariable stepwise logistic regression was employed to identify the potential socio-demographic associated factors. Of total 16,453 participants aged 25-75 years (75.43% from urban areas, 54.67% women), 58.01% (confidence interval (CI): 56.92-59.09) had no morbidity, 27.56% (26.59-28.55) had only one morbidity (HTN: 19.78%, T2DM: 6.02%, MI/Stroke: 1.76%), 11.73% (11.07-12.45) had two morbidities, and 2.68% (2.31-3.11) had all three morbidities. In total, the prevalence of cardiometabolic multimorbidity was 14.43% (13.67-15.22); and while being employed, wealthy, and having high educational level were negatively associated with the prevalent cardiometabolic multimorbidity, aging, urban residency, physical inactivity, central and general obesity, positive family history of MI/Stroke, positive family history of diabetes, and history of COVID-19 hospitalization had positive associations (all p-values < 0.05). Moreover, sex-stratified analyses showed similar results. As a limitation, history of MI/stroke was based on self-reported data. In conclusion, 14.43% of Iranian adults experience cardiometabolic multimorbidity with comparable prevalence between men and women, posing a considerable burden on public health and underscoring the necessity for pragmatic and multicomponent preventive strategies in both sexes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.